The new MDT facility opens at RPA

We were delighted to be invited to the opening of the new MDT facility at RPA for the Bone and Soft Tissue Sarcoma Unit.

Equipped with the latest technology to enhance patient care, the facility is dedicated to the memory of Dr Annabelle Mahar, a much loved, highly respected and world-renowned member of RPA’s Tissue Pathology Department.

Sarcoma is an insidious cancer, treatments are complex and it is the leading cause of cancer related deaths in the 15 to 24 year age group in Australia.(AIHW)

Equipping our brilliant sarcoma trained specialists with the space and technology to collaborate in weekly MDT meetings is a critical component of optimal patient care for those diagnosed with sarcoma.

Today marked an important step forward, and with it, tangible hope.

Dr Teresa Anderson delivered the opening words, acknowledging the work of Dr Annabelle Mahar, whose name the centre proudly bears, together with an outline of why this facility is needed.

Dr Stephen McNamara, devoted partner of Dr Annabelle Mahar’s heartfelt speech today resonated with all in the room. A plaque commemorating Annabelle’s immense contribution to pathology at RPA sits at the entrance to this facility.

After an illustrious career that saw him a pioneer in sarcoma surgery in Australia, Professor Paul Stalley has now passed the baton to incoming Chair of the NSW Bone and Soft Tissue Unit , Dr RIchard Boyle, who officially opened the facility with well chosen words expressing the significance of this facility.

We speak for all those touched by sarcoma in thanking Dr Teresa Anderson Chief Executive of the Sydney Local Health District, and NSW Health for this investment in the future of sarcoma in NSW.

Chris’ story of a Desmoid tumour diagnosis

In June of 2020 I noticed a very hard lump in my biceps area. I ignored it as I go to the gym regularly. My best friend Drew is a representative level athlete and knew it was not a sporting injury. He pushed me to call my mum. She made me immediately go to the GP.

The GP was very good and organised an immediate scan and ultrasound for the very next morning. That was a very stressful time for me. I was relieved to find out it was not Osteosarcoma or Fibrosarcoma like they were concerned about. It was put down to a muscle tear. My mother was not convinced and requested an urgent MRI the next day. The result came back as a rare 3 in a million desmoid tumour. It was very confusing. I was told I needed systemic chemotherapy and had to be seen by a Sarcoma Specialist yet it was not normal cancer. Rather a chronic sub form of sarcoma.

The sarcoma surgical team at Chris O’Brien Lifehouse were excellent. They fast tracked everything to be safe and knew not to remove the desmoid as can trigger its return with a vengeance. The necessary surgical biopsy however triggered it. Sometimes desmoids can turn off so a wait and see approach can be useful at times. It was clear mine was growing however and luckily my mother was doing extra MRIs.

Desmoids behave like sarcoma in every way apart from they rarely metastasise. They are locally aggressive and grow like a vine eating everything in their way . As they are aggressive when in the head, neck or intra abdominal areas they can be deadly. They often do not respond to chemotherapy or radiation. Just like other forms of sarcoma.

I did not want to face amputation or a lifetime on and off chemotherapy. Radiation was also being repeatedly suggested despite globally being the last treatment option due to the medium term risks of a deadly radiation induced sarcoma. I was determined to find another way as was my mother, and we were not OK with the suggested further wait and see approach when it was clearly growing.

Luckily we found out about an Israeli trial by Dr Eldad Elkanave via the wonderful support of the DTRF in America, and we switched teams. I felt a sense of relief I cannot adequately describe once I changed. Interventional Radiologist Dr Glen Schlaphoff from Spectrum Imaging/Director of Liverpool Hospital Interventional Radiology and Dr Antoinette Anazodo from Prince of Wales Children’s Hospital changed my life. They gave me hope. They both have the most outstanding patient centred approach alongside incredible medical knowledge and skill-sets in their fields. They backed my wish to have TACE (chemo-embolisation) followed by cryoablation.

I have had five procedures to date. My tumour had grown from 5cm by 2cm by 3cm to 15cm by 9cm by 10cm before treatment started in February 2021 under my new team. Dr Elkanave was involved from Israel which I will not forget. It is now back down to 5cm by 2cm by 2cm. I am the first patient in Australia to do this and first globally to do this first line treatment  for my tumour type. It has allowed me to get on with life in between treatments without the harsh cardiac, fertility, mental health and immune related side effects on systemic chemotherapy.

I would not have completed my HSC or now be at University likely without my parents, Glen and Antoinette’s determination to help change the trajectory of desmoid patient treatment outcomes. Antoniette attended every appointment – even regular check ups with my lovely burns nurse Alison. Their Oncology nurses Fiona and Cathy are the best too. Glen is my hero for the rest of my life!  There may not be a lot of fancy advertising but Prince of Wales Hospital walks the talk when it comes to comprehensive Oncology care for their adolescent patients. Many others with my tumour type are now choosing the TACE and Cryoablation treatment pathway where feasible globally which makes me so happy. I would like to work with stakeholders to see Cryoablation covered by private health funds like it is in the USA and Europe.

Lastly, I know my medical journey is not over. A desmoid tumour diagnosis is a chronic condition. One must have a warrior attitude. The reality is I have many battles ahead to win the war. It is so confronting to sit next to other patients with more deadly forms of sarcoma knowing what that prognosis means. Cooper was the same age as me when diagnosed. His tumour was in the same location.

It is just not OK that Osteosarcoma and Ewing’s Sarcoma have not seen improvements in 40 years. I will help in any way to change this.  Any progress with one form of sarcoma helps another form. For Cooper, for every patient I sit next to on my check up days, for all the rare desmoid patients, and future sarcoma patients I wish for nothing short of a cure ASAP and better support while we achieve that.

I want all patients to have doctors that are patient centred, have sound consultation skills, are determined by nature, and up to date with the latest clinical knowledge. Explaining ALL options available and involving patients in decision making is also key. I want patients who do not have parents who are skilled researchers to have somewhere to turn to in Australia. Be it private or public ALWAYS seek a second or third opinion if concerned and look into trials.

Always remember what extreme talent we have in our Teaching Hospitals! –  Christopher Sabahi 2022

Superheroes don’t always wear a cape

“I believe a real-life superhero is someone who has extraordinary or superhuman abilities or skills. They are people who deserve our gratitude.

During my cancer journey I could name a few, however right at the top of this list is my oncologist Professor Stewart Kellie, the best of the best in my eyes.

After being diagnosed on my 12th birthday with high grade metastatic osteoblastic osteosarcoma, I thank the universe every day for Prof Kellie being assigned to me.

He told me that over the next few months things were going to be tough, I would lose most of the bone in my leg and would have to undergo many rounds of chemotherapy to beat this disease (no different to anyone fighting this hideous disease). But he also promised me that he would always tell me the truth, he would never lie to me no matter how hard his news was. That I had to trust him always and we would get through it all together.

He kept his promise to me, he made me feel so safe and protected and I knew he had my back.

I had a lot of time to think about things while being treated. How dedicated the doctors and nurses were, wondered what their families were like, and how hard Prof Kellie must have worked to become the amazing man he was. I was grateful for him from the beginning.

After many operations and many months of chemotherapy it was also Prof Kellie who delivered the news to me that I was cancer free and I was able to go back home to my hometown, some 300km from the Sydney Children’s Hospital at Westmead.

When Prof broke this news to me, you can imagine the relief for me and those around me. In our last appointment before we left that day Prof said to me “Molly, any more questions before you go?”. I said “Yes Prof I have one. You are one of my real-life superheroes, and I’ve always wondered what superheroes eat. Prof what did you have for dinner last night?”.

We laughed, he answered my question, and I was lucky enough to go home shortly after.

When I relapsed more recently it was again my superhero Prof Kellie that delivered the news after a routine scan. I knew it upset him too, but he again had the ball rolling and I knew I was in the hands of the best.

After my surgery, where they removed the sarcoma nodules from my lung, one of the first people by my bedside on the ward was Prof Kellie.

When I spotted him I burst into tears. Prof said “I’m glad I don’t have this effect on all my patients Molly” before my Mum said “Moll why are you crying, Prof doesn’t make you sad does he?”. I responded with “No he doesn’t. He makes me feel safe and I’m so glad to see him”.

And that why he is my superhero – he is extraordinary, he is so skilful and super, super clever. Regardless of the news he has had to tell me, he has always made me feel safe and he deserves my gratitude.

So, Professor Kellie, this superheroes week for 2022, I hereby rename you – Superhero Professor Stewart Kellie.

You are my real-life superhero and I salute you. Today, always, and forever.” Molly Croft

City to Surf 2022 – registrations now open


It’s been a long lockdown. Let’s not put those Strava efforts to waste – dust off the runners, and join CRBF on 14 August for the 2022 @city2surf !!

Have a great day completing the 14km course at your own pace, while contributing funds to CRBF Patient Support.

Whilst we are dedicated to finding a cure for sarcoma, we are equally invested in reducing angst for patients and families during their sarcoma journey. We tailor our patient support to suit the individual and whatever their situation calls for. Head to https://www.crbf.org.au/patient-support/ to find out more about this service.

To sign up to for the #city2surf and raise funds for this vitally important service, please head to the link in our bio!

We appreciate this can be a confusing process so if you encounter any issues please don’t hesitate to reach out.

Official opening of the YouCan Centre, Chris O’Brien Lifehouse

A truly memorable event this morning at the unveiling of the  Sony Foundation You Can Centre at Chris O’Brien Lifehouse

This state of the art centre will provide first class apartment style accommodation at no cost for families of the 15-25 year olds (Adolescent Young Adults AYA’s) living with a cancer diagnosis, who are forced to travel to facilitate treatment.

It is estimated upwards of 25% of this group will be sarcoma patients.

The omnipresent and commanding image of Chris O’Brien watched over proceedings which began with the poignant and magnificently chosen words of Gail O’Brien AM, followed by a flawless speech by Sony Foundation CEO, Sophie Ryan; the Premier of NSW Dominic Perrottet and the Hon Brad Hazzard both spoke without hint of an impending election, but instead from the heart; while host Peter Overton, forever the consummate professional, shared his deeply personal connection with this critical project.

The star of the event however was nineteen year old osteosarcoma survivor Elliot Prasad who delivered the heartfelt words that could only come from those who have walked this road. Elliot held the room in the palm of his hand – sharing his experience whilst undergoing treatment at Chris O’Brien Lifehouse and articulating the importance of the You Can Centre to those walking this road behind him.

Our heartiest congratulations to all involved.

An enormous step forward for those young people living with a cancer diagnosis.

Aus Genomic screening and clinical trials $185m

An emotional yet uplifting morning at @garvaninstitute as @angustaylormp together with @greghuntmp (not present due to another commitment), announced a joint funding agreement of $185.4min for the ground-breaking vision of Professor David Thomas and the stellar team at @garvaninstitute to facilitate the Precision Oncology Screening Platform enabling Clinical Trials (PrOSPeCT).

It is difficult not to be emotional when you stop to consider the gravity and breadth of this programme, and what it will mean to those patients living with cancer in Australia, and in particular, rare cancers such as sarcomas.  Sarcoma patients live with the uncertainty of a ‘heterogenous’ cancer (prone to constant change), and genomic screening for genetic mutations, and the discovery of therapeutic matches (personalised therapeutics)  is a critical component of working toward a cure.

Speakers included the Garvan Institute’s Mara-Jean Tilley who managed to do the impossible by putting a very polished press conference together in less than 24 hours, the ever humble Professor David Thomas, The Honourable Angus Taylor MP, Minister for Minister for Industry, Energy and Emissions Reduction, Mr Stuart Knight, General Manager Roche, Dr Tony Penna representing NSW Health, Andrew Hagger CEO, Minderoo, Richard Vines CEO of Rare Cancers Australia and Omico Chair, Paul Jeans.  Each of the speakers spoke with deep passion about the programme, and the inherent difference it would make to those who need it most.

Some of the many aims of this programme are to provide both paediatric and adult patients increased access to genomic screening, (an additional 20,000 patients), repurposed drugs and immunotherapies, to empower Australian clinical trials innovation and capacity building, and to drive pharmaceutical and biotech engagement, establishing Australia as a world leader in this space.

By expanding the current programme to accommodate 20,000 additional patients, will provide untold hope to those who will over the coming months and years, be diagnosed with cancer.

The NSW @nswhealth and Federal Government(s) @healthgovau @industrygovau are to be acknowledged and thanked for their support of this programme, @childrenscancerinstitute for their contribution to the very important paediatric and AYA component, together with
@roche and philanthropic partners @minderoofoundation @rarecancers

IMG-0090
IMG-0100 (1)
IMG-0096
previous arrow
next arrow

Inter-Ewing-1 clinical trial

The Cooper Rice-Brading Foundation is delighted to be joining with The Kids Cancer Project once again, to provide funding support for a new international clinical trial for patients diagnosed with Ewing sarcoma that will be available soon to patients in Australia and New Zealand.

CRBF and TKCP join with the Federal Government Medical Research Futures Fund through Canteen and ANZCHOG, and the GPA Andrew Ursini Charitable Fund providing philanthropic support to ANZSA.

In a recent press release, CEO of The Kids Cancer Project, Owen Finegan said “The Kids’ Cancer Project and the Cooper Rice-Brading Foundation are proud to be providing funding for this exciting international clinical trial, which will help children across Australia and beyond benefit from access to new treatment strategies.”

 

Ewing sarcoma is a rare and highly aggressive tumour that forms in bone or soft tissue, which can affect all age groups, but hits our young (paediatrics, adolescents and young adults) disproportionately hard. Survival rates for localised disease currently sit between 65% – 75%, however for those patients with advanced disease, survival rates plummet as low as 25%.

INTER-EWING-1 is an international clinical trial that examines several new treatment strategies for Ewing sarcoma patients, including access to a novel agent (a tyrosine kinase inhibitor), optimising radiotherapy doses and adding “maintenance” chemotherapy at the end of other planned treatments for patients of all ages.

 

This study will involve an internationally renowned team of sarcoma researchers led by Bone Cancer Research Trust Trustee and world-renowned Consultant Paediatric Oncologist, Professor Bernadette Brennan and will be conducted throughout Europe, the United Kingdom, Israel and Australia, where Australian researchers have contributed to development of the trial.

The University of Birmingham will act as the International Sponsor for the INTER-EWING-1 trial, with ANZCHOG the National Sponsor for participating Australian and New Zealand paediatric and adult oncology centres. Associate Professor Geoff McCowage, Medical Oncologist Westmead Children’s Hospital, is Chief Investigator of this trial and has also recently joined the CRBF Medical Advisory Board, and brings a wealth of experience in sarcoma to this study.

STRASS 2 clinical trial receives MRFF funding

Eminent specialist surgical oncologist Associate Professor David Gyorki, together with Associate Professor Anne Hamilton, and colleagues from Royal Prince Alfred Hospital led by Associate Professor Peter Grimison, Princess Alexandra Hospital led by Professor Andrew Barbour collaborating with the national scientific body for sarcoma, ANZSA, have received a sizeable grant from the Medical Research Future Fund (MRFF) under the Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) scheme.

The grant is to run the international trial in Australia – “A randomised phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)”.

“Eligible Australian patients with retroperitoneal sarcoma at high risk of recurrence will be able to participate in this randomised controlled trial designed to answer the question of whether preoperative chemotherapy improves outcome for patients. The current standard of care for these patients is surgery alone. However, the risk of recurrence for many of them is 50% or higher.

The purpose of the STRASS 2 trial is to determine whether the administration of chemotherapy before surgery represents a better treatment compared to surgery alone and if the administration of chemotherapy before surgery is safe. It is also to assess whether specific chemotherapy can be used to reduce recurrence risk in a patient with either high-grade leiomyosarcoma or high-grade dedifferentiated liposarcoma. 

It is the first time a trial has studied the role of preoperative chemotherapy specifically in patients with retroperitoneal sarcoma, an anatomical location with unique challenges and disease patterns.” (ANZSA, July 2021)

The trial, led by the European Organisation for Research and Treatment of Cancer (EORTC) has participation from Europe, Canada, USA and now Australia.

“With aims to recruit 40 Australian patients, the STRASS 2 trial will open at Peter MacCallum Cancer Centre (VIC) as the lead site, with A/Prof Hamilton as the lead oncologist on the trial. The trial will also open at Royal Prince Alfred/Chris O’Brien Lifehouse (NSW) and at the Princess Alexandra Hospital (QLD).

About clinical trial

Please speak to your treating team about this clinical trial to see if you are eligible for it.

Remember that participation in a clinical trial is voluntary and that you should never feel forced to participate in it.

Before you agree to participate in a clinical trial, it is important to be as informed as possible. It can be helpful to write down questions you have before seeing your doctor.” (ANZSA, July 2021)

Please refer to the ANZSA website for further information by pressing the link below

https://sarcoma.org.au/news/news/successful-mrff-grant-for-strass-2-trial

Let’s talk “more” about sarcoma


Take 45 minutes out of your day to put your EarPods in, and listen to our latest Podcast, Let’s Talk More About Sarcoma, a collaboration between Sock it to sarcoma! and CRBF.

It may save your life or that of someone that you love.

In this episode we are delighted to have Dr Richard Boyle, eminent sarcoma surgeon, & the Head of NSW Bone & Soft Tissue Sarcoma Unit at RPAH, Dr Michela Sorensen, Dr Michela Sorensen, Medical Practitioner who has not only seen sarcoma in her practice, but has also suffered the unspeakable loss of a family member, and finally Merryn Aldridge, who worked as a physiotherapist for the Australian Athletic Team at the 2014 Commonwealth Games, and once again has encountered sarcoma through her practice. This highly credentialed trio speak about the importance of symptom recognition, your rights as a patient, and the importance of timely referral to a sarcoma specialist.

An enormous thank you to Cathrine Mahoney & Darcy Milne, the stellar team behind this podcast series for the second season. Suffice to say without their professionalism and willingness to assist us with this very important project, this production would not be possible.

To listen, please press on the link below:

https://podcasts.apple.com/au/podcast/lets-talk-more-about-sarcoma/id1521584488?i=1000527963130

Zero Children’s Cancer research grant


To mark the commencement of Global Sarcoma Awareness Month, it is our great pleasure to announce the “Wipfli Family Sarcoma Research Grant”, a $186,799 grant, made possible by the family’s incredible efforts throughout Celebrity Apprentice Australia.  But it doesn’t end there – joining with us is The Kids Cancer Project who have stepped in and doubled the grant.

All in all, $373,597 will be heading towards sarcoma specific research under the auspices of  the Children’s Cancer Institute of Australia  and the Zero Childhood Cancer Phosphoproteomic Study!

The study will be led by Dr Emmy Fleuren, the sarcoma research lead in the Translational Tumour Biology Group at the CCIA. Emmy is leading the way in the paediatric and adolescent space in Australia, and the future of sarcoma is all the better from having her expertise.

We need not remind you of the efforts of Wippa and Lisa to facilitate the money raised throughout Celebrity Apprentice.  They are an incredibly special family, and their efforts to grow Cooper’s legacy is inspirational.

The Kids Cancer Project, with a special mention to CEO Owen Finegan, have supported high level paediatric, adolescent and young adult cancer research in Australia for almost three decades.  Their commitment to funding research projects for all childhood cancers is as humbling as it is life-changing for those young patients who stand to benefit.

We extend our deepest gratitude to each of these outstanding contributors to sarcoma research in Australia.

Head to the Children’s Cancer Institute social media accounts to read more about the research!